NCT00770445 - Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus. | Biotech Hunter

Enrollment

121

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions

Diabetes Mellitus

Interventions

DRUG

Pioglitazone and insulin

Pioglitazone 15 mg, tablets, orally, twice daily and metformin placebo-matching tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.

DRUG

Pioglitazone and metformin and insulin

Pioglitazone 15 mg, tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.

DRUG

Metformin and insulin

Pioglitazone placebo-matching tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.

Trial Locations (18)

Unknown

Lichtenfels

Hamburg

Frankfurt am Main

Kassel

Wiesbaden

Bad Oeynhausen

Dinslaken

Duisburg

Essen

Münster

Wuppertal

Diez

Landau

Mainz

Dresden

Leipzig

Berlin

Jena